Sodium Salicylate Inhibits Proliferation and Induces G1 Cell Cycle Arrest in Human Pancreatic Cancer Cell Lines

Journal of Gastrointestinal Surgery

Volumn 4, Issue 1, 2000, Pages 24-33

  Perugini, Richard A ^a   McDade, Theodore P ^a   Vittimberga Jr , Frank J ^a   Duffy, Andrew J ^a   Callery, Mark P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cell cycle; Cyclin D1; NSAID; Pancreatic adenocarcinoma; Sodium salicylate

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIN D1; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOCARCINOMA; ARTICLE; CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL SEPARATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MUTATION; PANCREAS TUMOR; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOTTING, WESTERN; CELL DIVISION; CELL SEPARATION; CYCLIN D1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G1 PHASE; HUMANS; MUTATION; PANCREATIC NEOPLASMS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0033632037     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1091-255x(00)80029-3     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. Ann Surg 1997;225:621-36.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-364.
4. Perugini RA, McDade TP, Vittimberga FJ, Callery MP. Molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryot Gene Expr 1998;8:377-393.
5. Bos JL. p21ras: An oncoprotein functioning in growth factor-induced signal transduction. Eur J Cancer 1995;31A:1051-1054.
6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
7. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166:7-12.
8. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR. High frequency of Kiras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-1041.
9. Pronk GJ, Bos JL. The role of p21ras in receptor tyrosine kinase signalling. Biochim Biophys Acta 1994;1198:131-147.
10. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-3033.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-704.
13. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacring protein Cip21 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
14. Chen Z, Zhang H, Savarese T. Gene deletion chemoselectivity: Codeletion of the genes for p16 (INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 1996;56:1083-1090.
15. Huang L, Goodrow T, Zhang S, Klein-Szanto A, Chang H, Ruggeri B. Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56:1137-1141.
16. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996;110:1215-1224.
17. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
18. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, et al. The Ink4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes inhibition of p53. Cell 1998; 92:713-723.
19. Trujillo MA, Garewal HS, Sampliner RE. Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost? Dig Dis Sci 1994;39:2260-2266.
20. Giardiello FM, Offerhaus GJA, DuBois RN. The role of nonsteroidal antiinflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31A:1071-1075.
21. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 1997;115: 229-234.
22. Shiff SJ, Qiao L, Tsai L-L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
23. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 1996;222:179-188.
24. IIanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-dependent pathway. Biochem Pharmacol 1996;52:237-245.
25. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-2459.
26. Elder DE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996;56:2273-2276.
27. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U.S.A. 1987;84:1417-1420.
28. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russel RCG, Neoptolemos J, Williamson RCN, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64:1076-1082.
29. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-191.
30. Berger DH, Jardines LA, Chang H, Ruggeri B. Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 1997; 69:199-204.
31. MAPK pathway. J Biol Chem 1996;271:20608-20616.
32. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237:1-6.
33. Tietz NW, Tietz NW, ed. Fundamentals of Clinical Chemistry. Philadelphia: WB Saunders, 1976, p 1148.
34. McDade TP, Perugini RA, Vittimberga FJ, Carrigan RC, Callery MP. Salicyktes inhibit NF-kB activation and enhance TNF-a-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999;83:56-61.
35. Mitchell JA, Akarasereenont P, Thiermermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1993;90:11693-11697.